Clearside Biomedical(CLSD) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Recent ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieved All Primary and Secondary Outcomes - - Positive Topline Results Support Advancing CLS-AX to Phase 3 Targeting a Differentiated Flexible Dosing Approach Similar to a Biologic with the Potential Extended Duration of a Tyrosine Kinase Inhibitor (TKI) - - Recent Commercial Licensing Agreement for China by a Global Ophthalmic P ...